In addition, CAF-released factors influence the development of therapy resistance by inducing anti-apoptotic mechanisms in both estrogen receptor α positive (ERα+) and negative (ERα−) breast cancer cells exposed to anti-cancer drugs [5,6]. Here, ESR1 is linked to breast carcinoma.